Society for healthcare epidemiology of america and infectious diseases society of america joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals

Clinical Infectious Diseases

Volumn 25, Issue 3, 1997, Pages 584-599

  Shlaes, David M ^a   Gerding, Dale N ^a   John Jr , Joseph F ^a   Craig, William A ^a   Bornstein, Donald L ^a   Duncan, Robert A ^a   Eckman, Mark R ^a   Farrer, William E ^a   Greene, William H ^a   Lorian, Victor ^a   Levy, Stuart ^a   McGowan Jr , John E ^a   Paul, Sindy M ^a   Ruskin, Joel ^a   Tenover, Fred C ^a   Watanakunakorn, Chatrchai ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM; CROSS INFECTION; DRUG EFFECT; GENETICS; HOSPITAL; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MICROBIOLOGY; PATHOGENICITY; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; UNITED STATES; VIRULENCE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; HOSPITALIZATION; HOSPITALS; HUMANS; PATIENT ISOLATION; SOCIETIES, MEDICAL; UNITED STATES; VIRULENCE;

EID: 0031225237     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513766     Document Type: Article

References (84)

1. Shlaes DM, Levy S, Archer G. Antimicrobial resistance: new directions. ASM News 1991:57:455-63.
2. Phelps CE. Bug/drug resistance. Med Care 1988;27:194-203.
3. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
4. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264:375-82.
5. Stokes HW. Hall RM. A novel family of potentially mobile DNA elements encoding site-specific gene integration functions: intégrons. Mol Microbiol 1989;3:1669-83.
6. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994:264:382-8.
7. Levy SB. Active efflux mechanisms of antibiotic resistance. Antimicrob Agents Chemother 1992:36:695 703.
8. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994;264:388-93.
9. Musher DM, Baughn RE, Templeton GB, Minuth JN. Emergence of variant forms of Staphylococcus aurens after exposure to gentamicin and infectivity of the variants in experimental animals. J Infect Dis 1977; 136:360-9.
10. Musher DM, Baughn RE. Merrell GL. Selection of small-colony variants of Enterobacteriaceae by in vitro exposure to aminoglycosides: pathogenicity for experimental animals. J Infect Dis 1979; 140:209- 14.
11. Balwitt JM. van Langevelde P, Vann JM, Proctor RA. Gentamicin-resistant menadione and hemin auxotrophic Staphvlococcus aiireiia persist within cultured epithelial cells. J Infect Dis 1994; 170:1033-7.
12. Müder RR. Brennen C. Wagener MW, et al. Methicillin-resistant staphylococcal colonization and infection in a long term care facility. Ann Intern Med 1991:114:107-12.
13. Garner .IS, Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996:17:53-80.
14. Wingard E, Shlaes JH, Mortimer EA, Shlaes DM. Colonization and crosscolonization of nursing home patients with trimethoprim-resistant gramnegative bacilli. Clin Infect Dis 1993; 16:75-81.
15. McGowan JE Jr. Antibiotic resistance in hospital bacteria: current patterns, modes for appearance or spread, and economic impact. Rev Med Microbiol 1991;2:161-9.
16. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033-48.
17. Olson B, Weinstein RA, Nathan C, Gaston MA, Kabins SA. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis 1987; 150:808-16.
18. McGowan JE Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med 1987;63:253-68.
19. Levy SB. Balancing the drug-resistance equation. Trends Microbiol 1994; 2:341 2.
20. Courcol RJ, Pinkas M, Martin GR. A seven-year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989:23:441-51.
21. Duncan RA, Steger KA. Craven DE. Selective decontamination of the digestive tract: risks outweigh benefits for intensive care unit patients. Semin Respir Infect 1993:8:308-24.
22. Hughes WT, Armstrong D, Bodey OP. et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990:161:381-96.
23. Kim JH, Gallis HA. Observations on spiraling empiricism: its causes, allure, and perils with particular reference to antibiotic therapy. Am J Med 1989:87:201-6.
24. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol 1993; 14:376-82.
25. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992; 17:303-5.
26. Moller JK. Antimicrobial usage and microbial resistance in a university hospital during a seven-year period. J Antimicrob Chemother 1989; 24: 983-92.
27. Sallow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance report of the national nosocomial resistance surveillance group. Diagn Microbiol Infect Dis 1992; 15:375-425.
28. Coronado VG, Edwards JR, Culver DH, Gaynes RP. Ciprofloxacin resistance among nosocomial Pseitdomonas aentginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16:71 -5.
29. Goswitz JJ, Willard K.E, Fasching CE, Peterson LR. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillinresistant Stap/ivlococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother 1992:36:1166-9.
30. Ferrero L, Cameron B, Manse B. et al. Cloning and primary structure of Staphvlococats aureus DNA topoisomerase. IV: a primary target of fluoroquinolones. Mol Microbiol 1994:13:641-53.
31. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grl.4 mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphviococciis aureus. Antimicrob Agents Chemother 1995:39:1554 8.
32. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15:478-83.
33. Belts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglvcoside usage in a university hospital. Ann Intern Med 1984; 100:219-22.
34. Gerding DN, Larson TA, Hughes RA. et al. Aminoglvcoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991:35:1284 90.
35. Berk SL, Alvarez S, Ortega G, et al. Clinical and microbiological consequences of amikacin use during a 42-month period. Arch Intern Med 1986:146:538 41.
36. Young EJ, Sewell CM, Koza MA, Clarridge JE. Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sei 1985;290: 223-7.
37. King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992:14:908-15.
38. van Landuyt HW, Boelaert J, Glibert B, Cordts B, Verbruggen AM. Surveillance of aminoglycoside resistance: European data. Am J Med 1986; 80(suppl 6B):76-81.
39. Bamberger DM, Dahl SL. Impact of voluntary vs enforced compliance of third-generation cephafosporin use in a teaching hospital. Arch Intern Med 1992; 152:554-7.
40. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272 -7.
41. Hammond JMJ, Potgieter PD, Forder AA, Plumb H. Influence of amikacin as the primary aminoglycoside on bacterial isolates in the intensive care unit. Crit Care Med 1990:18:607-10.
42. Friedland IR, Funk E, Khoosal M, Klugman KP. Increased resistance to amikacin in a neonatal unit following intensive amikacin usage. Antimicrob Agents Chemother 1992:36:1596 1600.
43. Levine JF, Maslow MJ, Leibowitz RE, et al. Amikacin-resistant gramnegative bacilli: correlation of occurrence with amikacin use. J Infect Dis 1985; 151:295-300.
44. Moody MM, de Jongh CA, Schimpff SC, Tillman GL. Long-term amikacin use: effects on aminoglycoside susceptibility patterns of gram-negative bacilli. JAMA 1982;248:1199-1202.
45. McGowan JE Jr. Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control 1986;7: 573-76.
46. Saravolatz LD, Arking L, Pohlod D, et al. An outbreak of gentamicinresistant Klebsiella pneumoniae: analysis of control measures. Infect Control 1984; 5:79-84.
47. Craig WA. Do antibiotic combinations prevent the emergence of resistant organisms? Infect Control Hosp Epidemiol 1988;9:417-9.
48. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
49. Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105-13.
50. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353-8.
51. Sahm DF, O'Brien TF. Detection and surveillance of antimicrobial resistance. Trends Microbiol 1994;2:366-71.
52. Occupational Safety and Health Administration, Department of Labor. Occupational exposure to bloodborne pathogens. Final rule. Federal Register 1991;56:64175-82.
53. Lynch P, Cummings MI, Roberts PL, et al. Implementing and evaluating a system of generic infection precautions: body substance isolation. Am J Infect Control 1990; 18:1-12.
54. Centers for Disease Control. Update: Universal Precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in health care settings. MMWR 1988; 37: 377-382, 387-8.
55. Cimino MA, Rotstein CM, Mosder JE. Assessment of cost effective antibiotic therapy in the management of infection in cancer patients. Ann Pharmacother 1994;28:105-11.
56. Neu HC. Antimicrobial agents. In: Wenzel RP, ed. Role in the Prevention and Control of Nosocomial Infection. 2nd ed. Baltimore, MD: Williams & Wilkins 1993:406-19.
57. Stern Z, Simchen E, Shapiro M, Sacks T, Ferderber N. The role of a hospital director in efforts to reduce infections after surgical procedures: a report of intervention in cardiac surgery. Clinical Performance and Quality Health Care 1994;2:135-40.
58. Eisenberg JM. New drugs and clinical economics: analysis of cost effectiveness in the assessment of pharmaceutical innovations. Rev Infect Dis 1984;6:S905-8.
59. Pelletier LL. Hospital usage of parenteral antimicrobial agents: a graduated utilization review and cost containment program. Infect Control 1985; 6:226-30.
60. Liss RH, Batchelor FR. Economic evaluation of antibiotic use and resistance-a perspective: report of task force 6. Rev Infect Dis 1987;9: S297-S312.
61. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health-Syst Pharm 1995;52:1433-5.
62. Evans RS, Pestotnik SL, Burke JP, Gardner RM, Larson RA, Classen DC. Reducing the duration of prophylactic antibiotic use through computer monitoring of surgical patients. Ann Pharmacother 1990; 24:351-4.
63. Soumerai SB, Lipton HL. Computer-based drug utilization review-risk, benefit, or boondoggle? [comment]. N Engl J Med 1995;332:1641-5.
64. Zaza S, Jarvis WJ. Investigation of outbreaks. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Williams & Wilkins; 1996:105-13.
65. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antibiotic-resistant microorganisms in hospitals-a challenge to hospital leadership. Workshop to prevent and control the emergence and spread of antibiotic-resistant microorganisms in hospitals. JAMA 1996; 275:234-40.
66. Weinstein RA, Kabins SA. Strategies for prevention and control of multiple drug-resistant nosocomial infection. Am J Med 1981;70:449-54.
67. Mace D, Walton MH. Establishing local policy for formulary management. VA Practitioner 1984;4:52-7.
68. Gould IM, Hampson J, Taylor EW, Wood MJ. Working Party Report: Hospital antibiotic control measures in the UK. J Antimicrob Chemother 1994; 34:21-42.
69. Report of the ASM Task Force on antibiotic resistance. Washington, DC: American Society for Microbiology, 1995.
70. Dellinger EP, Gross PA, Barren TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infect Control Hosp Epidemiol 1994; 15:182-8.
71. Paul SM, Finelli L, Crane GL, Sitalny KC. A statewide surveillance system for antimicrobial resistance bacteria: New Jersey. Infect Control Hosp Epidemiol 1995; 16:385-90.
72. Ives TJ, Frey JJ, Furr SJ, Bentz EJ. Effect of an education intervention on oral cephalosporin use in primary care. Arch Intern Med 1987; 147: 44-7.
73. Evans RS, Larsen RA, Burke JP, et al. Computer surveillance of hospitalacquired infections and antibiotic use. JAMA 1986;256:1001-7.
74. Durbin WA, LaPidas B, Goldmann DA. Improved antibiotic usage following introduction of a novel prescription system. JAMA 1981; 246:1796800.
75. Echols RM, Kowalsky SF. The use of an antibiotic order form for antibiotic utilization review: influence on physicians' prescribing patterns. J Infect Dis 1984;6:803-7.
76. Ma MY. Meeting the challenge of rising antibiotic costs. VA Practitioner 1984; 10:63-5.
77. DeVito JM, John JF. Effect of formulary restriction of cefotaxime usage. Arch Intern Med 1985; 145:1053-6.
78. Woodward RS, Medoff G, Smith MD, Gray JL. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical school-affiliated hospital. Am J Med 1987;83:817-23.
79. Nickman NA, Blissenbach HF, Herrick JD. Medical committee enforcement of policy limiting postsurgical antibiotic use. Am J Hosp Pharm 1984;41:2053-5.
80. Schentag JJ, Sallow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993; 16:255-64.
81. Achusim LE. Antibiotic use following implementation of a therapeutic interchange program. Pharmacol Ther 1992; 17:775-98.
82. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans' Affairs Medical Center from 1987 to 1989. Am J Med 1990;90:439-44.
83. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988; 148: 2019-22.
84. Rubenstein E, Barzilai A, Segev S, Samra Y, Modan M, Dickerman O. Antibiotic cost reduction by providing cost information. Eur J Clin Pharmacol 1988;35:269-72.